Investigators compared expression in different men across the genes from three commercial panels, arguing that the findings highlight important unknowns.
While higher recurrence scores have been associated with increased mortality in women, the pattern of the association differed among male patients.
The company reported increase US and international revenues and test volumes, driven by increased adoption and expanding public and private payor coverage.
The firm reported that test volumes for its Cologuard colorectal cancer screening test rose 89 percent year over year.
After the merger closes, the combined company will be split into four units focused on Cologuard, Oncotype Dx, international business, and pipeline efforts.
The new analysis has confirmed earlier evidence that patients with high Oncotype DX risk scores appear to benefit significantly from added chemotherapy.
The index, which underperformed the Dow Jones and the Nasdaq, gave back the 11 percent gain it made in June.
Financial analysts seemed convinced of the long-term advantages of the deal but noted that investors may remain skeptical in the near term.
The company's total revenues were $114.1 million compared with $95.6 million in the same quarter last year, beating analysts' expectations.
Exact said it will pay $72 per share for Genomic Health for a total transaction price of $2.8 billion in cash and stock.
Researchers are sampling the wild relatives of modern crops to try to preserve genetic diversity, NPR reports.
MIT's Search for Extraterrestrial Genomes is developing sequencing tools to use to try to detect whether there is any life on Mars, Quartz reports.
Undark reports on a bill introduced this year to the US House of Representatives to strengthen scientific integrity.
In Genome Research this week: post-zygotic mutations in diabetes development, single-cell RNA sequencing study of aging, and more.